Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen, Inc. (NASDAQ: OCGN) reported its first quarter 2020 financial results, highlighting the successful completion of patient enrollment in its Phase 3 trial for OCU300, aimed at treating ocular Graft vs. Host Disease. Topline results are expected by year-end. The company completed a warrant exchange, simplifying its capital structure and enhancing fundraising capabilities. As of March 31, 2020, Ocugen's cash reserves stood at $3.3 million. The net loss for Q1 2020 was $3.9 million, an improvement from $6.3 million in Q1 2019, with research expenses reduced to $1.7 million.